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Abstract. Heart failure is one of the major cause of patient’s admittance to the hospital. 
Primary hypertension is one of the most universal comorbidities that precedes heart 
failure and is one of the more common risk factors held by the majority of the 
population. Right now, antihypertension that are generally used is from Angiotensin-
Converting Enzyme Inhibitor (ACE-I) and Angiotensin Receptor Blocker (ARB). A new 
group of an antihypertensive agent called “Angiotensin Receptor Neprilysin Inhibitor 
(ARNI)” to further improve the patient condition. This study aims to evaluate the 
effectivity of ARNI against ACE-I regarding its cardiac reverse remodeling effect. 
Search strategy was done using electronic databases, which are Pubmed, Scopus, and 
Cochrane. Articles included are therapeutic study that is in line with the clinical 
question and fulfills the inclusion and exclusion criteria. Critical appraisal was done by 
assessing the article’s validity, importance, and applicability according to Oxford 
Center of Evidence-Based Medicine 2011 to two chosen articles. 2 articles are chosen 
and appraised. Both of the study are shown to be valid and shows that ARNI has a 
significantly better result on improving cardiac reverse remodeling via the left ventricle 
ejection fraction compared to ACE-I. However, the applicability of ARNI is still 
debatable in Indonesia as it was not covered by national insurance and there is no 
generic form. ARNI shows to be significantly better to reverse cardiac remodeling 
compared to ACE-I, but its applicability has to be improved to be implemented in 
Indonesia. 
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Abstrak. Gagal jantung merupakan salah satu penyebab utama pasien masuk rumah 
sakit. Hipertensi primer adalah salah satu komorbiditas paling universal yang 
mendahului gagal jantung dan merupakan salah satu faktor risiko yang umum 
dipegang oleh sebagian besar populasi. Saat ini antihipertensi yang banyak digunakan 
adalah dari Angiotensin-Converting Enzyme Inhibitor (ACE-I) dan Angiotensin 
Receptor Blocker (ARB). Sekelompok baru agen antihipertensi yang disebut 
"Angiotensin Receptor Neprilysin Inhibitor (ARNI)" untuk lebih meningkatkan kondisi 
pasien. Penelitian ini bertujuan untuk mengevaluasi efektivitas ARNI terhadap ACE-I 
terkait efek remodeling balik jantung. Strategi pencarian dilakukan dengan 
menggunakan database elektronik yaitu Pubmed, Scopus, dan Cochrane. Artikel yang 
termasuk adalah studi terapeutik yang sejalan dengan pertanyaan klinis dan memenuhi 
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kepentingan, dan penerapan artikel menurut Oxford Center of Evidence-Based 
Medicine 2011 untuk dua artikel yang dipilih. 2 artikel dipilih dan dinilai. Kedua 
penelitian tersebut terbukti valid dan menunjukkan bahwa ARNI memiliki hasil yang 
jauh lebih baik dalam meningkatkan remodeling balik jantung melalui fraksi ejeksi 
ventrikel kiri dibandingkan dengan ACE-I. Namun, penerapan ARNI masih 
diperdebatkan di Indonesia karena tidak tercakup oleh asuransi nasional dan tidak ada 
bentuk generiknya. ARNI menunjukkan jauh lebih baik untuk mengembalikan 
remodeling jantung dibandingkan dengan ACE-I, tetapi penerapannya harus 
ditingkatkan untuk diterapkan di Indonesia. 
Kata kunci:  ACEI, ARNI, Efektivitas, Gagal Jantung 
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I. Introduction 
Heart failure is one of the most common chronic health problem that could be faced around the 
world, and one the major cause of patient’s admittance to the hospital. Until now, heart failure 
still has an immense morbidity and mortality level, whether it’s in a developed or developing 
country, which includes Indonesia. According to a study by Bui A, et al and Vos T, et al, there 
are 37.7% of the world population that suffers from heart failure.[1,2]  
In the US alone, there are 5.7 million cases of heart failure in 2011, and there are 870.000 new 
cases each year [3,4] while in Indonesia, Riset Kesehatan Dasar in 2018 shows that the 
prevalence of diagnosed heart disease was 1.5% of the population [5]. Chronic heart failure is 
a condition where the heart lost its ability to function normally. The inability to pump blood 
from the heart to the body and lungs cause several manifestations, such as dyspnea and edema, 
although these symptoms were not specifics to this particular condition. The accumulation of 
symptoms can be caused by the anatomical changes in the heart, which can be irreversible.[6] 
Heart failure could be influenced by various risk factors. Several distinct factors are diet, 
physical activity, and other metabolic conditions, for instances like dislipidemia, diabetes 
mellitus, and hypertension.[7]  
Primary hypertension is one of the most universal comorbidities that precedes heart failure and 
is one of the more common risk factors held by the majority of the population. High blood 
pressure itself could lead to hypertensive heart disease, a group of disorders encompasses the 
complication of hypertension. Hypertension could increase the risk of heart failure development 
through increasing the heart’s workload and causing left ventricular hypertrophy. As such, 
hypertension and heart failure are almost always interconnected and cannot be separated. [6,7] 
To control hypertension, the primary intervention that could be done is through dietary control 
and increasing physical activity, but it is not uncommon to use medication as a primary 
modality to control hypertension. Right now, antihypertension that are generally used is from 
Angiotensin-Converting Enzyme Inhibitor (ACE-I), Angiotensin Receptor Blocker (ARB). 
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can be used as a single or combine treatment for hypertension, although usually, the first line 
used is ACE-I and ARB. [6,7] 
This evidence-based case report will try to highlight the effectivity of a new group 
―Angiotensin Receptor Neprilysin Inhibitor (ARNI)‖ to control hypertension in patients with 
chronic heart failure. As a new group of drug, ARNI works by inhibiting neprilysin, a neutral 
endopeptidase compound that takes part in the degradation of a vasoactive peptide-like 
natriuretic peptide and adrenomedullin. [8] By inhibiting neprilysin, the level of vasoactive 
peptides will increase, thus causing vasodilatation and decreasing the extracelullar volume 
through the excretion of natrium. [9] This drug will be compared to the first line to control 
hypertension, which is ACE Inhibitor. 
2. Case report 
Mr. Z, 41 years old, came to the emergency ward RSCM (Cipto Mangunkusumo Hospital) with 
worsening shortness of breath since 3 days before admittance. Shortness of breath was felt 
mainly during the night and worsen with activity. The patient frequently woke up during his sleep 
because of the same complaint. Shortness of breath is not influenced by the position and can be 
felt throughout the day. Right now the patient needed an extended position to sleep comfortably. 
The patient has been diagnosed with congestion in his heart since a year ago in Cibinong 
General Hospital, and routinely visit the hospital monthly for control. A week ago, the patient 
was admitted to RSCM because of the same complaint. 
In physical examination, the patient was found to be Compos Mentis and appeared as 
moderately sick. Blood pressure 123/74 mmHg, heart rate 118x/minute, respiratory rate 
28x/minute. In the facial examination, sclera was found anicteric but the conjunctiva was pale. 
JVP was 5+1 cm H2O, with no enlargement of the thyroid gland or lymph node.  In  thorax  
examination,  an  enlargement  of the heart  was  found  during the percussion of the margin 
of the heart, with normal sound during auscultation with no gallop or murmur. In lungs 
examination, the sound was vesicular-vesicular, but rales was heard in the right lung. In the 
abdominal examination, the abdomen looks flat, with no liver or spleen was palpable. 
Ballottement test and shifting dullness were negative. In the extremity, pitting oedema was 
found in both legs. 
In laboratory examination, it was found Hb was 10.4 g/dL and Ht 34.7. Leucocyte level was 
8180/mm3, and thrombocyte was 331.000/mm3. MCV/MCH was 67.9/22.3. In plain imaging 
of the thorax, cardiomegaly with lung edema was found, with right pleural effusion. 
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―How is The Effectiveness of Angiotensin Receptor Neprilysin Inhibitor on improving the 
cardiac remodeling compared to Angiotensin Receptor Blocker on patients with chronic heart 
failure?‖ 
Table 1. PICO 
PICO Population Intervention Comparison Outcome 

















Treatment    
Study Design Meta-analysis, systematic review, clinical trial, RCT 
 
4. Methods 
4.1 Research Strategy 
The literature search was used to identifying relevant study using 3 electronic databases, which is 
Pubmed, Cochrane, and Proquest. Keywords used are the combination of ―Chronic heart 
failure‖, ―Angiotensin Receptor Neprilysin Inhibitor‖, ―Angiotensin- Converting Enzyme 
Inhibitor‖, and ―Cardiac Remodelling‖ with their matching equivalent that is combined using 
Boolean operation (Table 1). The search strategy from each of the database is not restricted with 
any specific limitation 
Tabel 2 Search strategy on 3 databases and articles chosen. 
Database Terminology Search Result Selected 
Pubmed (((((((heart failure Or Congestive heart failure OR chronic heart failure OR "heart 
failure, systolic"[Mesh] OR Systolic Heart Failure OR heart failure with reduced 
ejection fraction)) AND (Angiotensin-Receptor Neprilysin Inhibitor OR Sacubitril OR 
Sacubitril-valsartan OR LCZ696 OR LCZ-696 OR entresto OR Angiotensin Receptor 
Neprilysin Inhibitor OR Neprilysin)) AND (Angiotensin Converting Enzyme Inhibitor 
OR Angiotensin-converting Enzyme Inhibitor OR ACE Inhibitor OR ACE I OR 
ACE-I OR Angiotensin- Converting Enzyme Antagonists OR Angiotensin- 
Converting Enzyme Antagonists)) AND (Cardiac remodelling OR myocard 
remodelling OR cardiac reverse  remodelling  OR  Cardiac  remodeling  OR 
myocard remodeling OR cardiac reverse remodeling)))) 
51 6 
Cochrane (chronic heart failure OR congestive heart failure OR heart failure) AND (angiotensin 
receptor neprilysin inhibitor OR angiotensin-receptor neprilysin inhibitor OR Arni OR 
sacubitril OR entresto OR Valsartan-sacubitril OR LCZ696 OR LCZ-696) AND 
(angiotensin converting enzyme inhibitor OR ACEI OR ACE-I OR ACE I OR 
angiotensin- converting enzyme inhibitor) AND (cardiac remodelling OR myocard 
remodelling OR cardiac function OR cardiac reverse remodelling)" 
7 2 
Scopus chronic  AND heart  AND failure  OR  congestive AND heart  AND failure  OR  
heart  AND failure AND  angiotensin  AND receptor  AND neprilysin AND inhibitor   
OR   angiotensin-receptor   AND neprilysin  AND inhibitor  OR  arni  OR  sacubitril 
OR  entresto  OR  valsartan-sacubitril  OR  lcz696 OR  lcz-696  AND  
angiotensin   AND converting AND enzyme  AND inhibitor  OR  acei  OR  ace-i 
OR  ace  AND i  OR  angiotensin-converting  AND enzyme   AND inhibitor   AND   
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function  OR  cardiac  AND reverse AND remodelling 
 
4.2 Article Selection 
Table 2 concludes the process of article selection. The total articles found from 3 
databases are 147 articles. The process of selecting the articles was done through these steps: 1. 
Selection based on the title and abstracts, 2. Selection based on duplicated articles, 3. Selection 
based on the completed reading of the articles. For the first part, the selection based on the title 
and abstracts will be adjusted to the inclusion and exclusion criteria that have been selected 
before. The inclusion criteria include published therapeutic studies that use RCT, systematic 
review, or meta- analysis methods, have objective parameters, and relevant to our clinical 
question. The exclusion criteria include animal studies, known-English studies, and another 
disease outside of heart failure.  From this inclusion and exclusion, 9 studies were found to be 
suitable. From these articles, duplicate articles were filtered from the databases. Articles without 
access to the full text were filtered and were further screened on the research relevancy with the 
variables listed with the clinical question. From the screening, 2 articles were deemed 
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Figure 1. Article Selection Process 
4.3 Clinical Appraisal 
Articles chosen were appraised to evaluate the quality of the published articles. The appraisal 
was done using Oxford Center for Evidence-Based Medicine 2011 criteria that include validity, 
importance, and applicability aspects from said studies. 
Chosen Articles 
1. Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D. Effects of the Angiotensin- 
Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis. J 
Am Heart Assoc. 2019;8(13):e012272. 
2. Gonzales-Torres L, De Diego C, Centurion R, Macias M, De Lara G, Carrasco 
R, Almendral J. Angiotensin-neprilysin inhibition further reverses cardiac 
remodeling as compared to angiotensin inhibition in reduced heart failure 
patients. Clinical Cardiology Journal Volume II. 2018 
5. Results 
5.1 Validity 
In its validity aspect, the study from Wang et al (2019) is deemed to be valid (Table 3.). The 
PICO from this study showed a clear connection between its population, which is patients with 
heart failure with reduced ejection fraction or preserved ejection fraction, its intervention, that 
compares the usage of ARNI and ACE-I, and the outcome of the study which is Cardiac reverses 
remodeling indices (LVEF). This study used major databases for its search strategy, with 
clearly defined inclusion and exclusion criteria. Finally, the study was proven to be 
homogenous from its results. 
Table 3.  Critical Appraisal on validity aspect of meta-analysis Wang et al (2019) 
Parameter Wang et al (2018) 
Was  the  clinical question(PICO) clearly and specifically 
defined    (+) 
The  PICO  in  this  article  were  clear  and showed  a  clear 
connection between the intervention and intended outcome 
P: Patients with heart failure with reduced ejection fraction or 
preserved ejection fraction (HreFR or HRpFR) 
I: Angiotensin-Receptor Neprilysin Inhibitor C: Angiotensin-
Converting Enzyme Inhibitors O: Cardiac reverses remodeling 
indices (LVEF) 
Were the groups similar at the start of the trial? (+) In patient characteristics table, similar baseline characteristics 
of the patients can be seen in all of the aspects, as the subjects 
were the same 
Aside    from    the    allocated treatment, were groups treated 
equally?  (+) 
The patients received the same dose of medication of ACE 
Inhibitor for 9 months, continued with ARNI for a further 9 
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18 months. 
Were all patients who entered the trial accounted for? And 
were   they   analyzed   in   the groups  to   which   they  
were randomized? (+) 
All of the patients were accounted for, and no patient was loss to 
the follow-up 
Were measures objective or were the patients and clinicians kept 
―blind‖ to which treatment was being received? (-) 
 
The measures were objective where the outcome measured was 
LVEF and LVDD using echocardiography, however, as it was 
a prospective study, both patients and clinicians were aware of 
the treatment received 
Level of Evidence 1b 
5.2 Importance 
In Wang et al study(Table 3), it was shown that there is a significant difference of cardiac 
reverse remodeling in ARNI and ACE-I, in which the left ventricle ejection fraction level in 
ACE-Inhibitor was found to be significantly lower than the one that used ARNI(p-value 
<0.00001). This result was in line with the results from Gonzales- Torres et al study, where they 
use 2D and 3D echocardiography parameter to calculate the left ventricle ejection fraction. 
Gonzales-Torres et al also show that patients treated with ARNI have significantly better LVEF 
volume in comparison to the use of ACE- Inhibitor alone (p-value <0.002). 
Table 4. Critical Appraisal of importance aspect of meta-analysis Wang et al (2019 
Cardiac Reverse 
Remodelling Parameter in 
ARNI vs ACEI 
P-value Mean Difference (95% 
CI) 










Figure 2. Forrest plot on Effectivity of ARNI against ACE-I on LVEF from Wang et al (2019)  
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Cardiac Reverse 
Remodelling Parameter in 
ARNI vs ACEI 
P-value Mean Difference (95% 
CI) 






Figure 3. Sacubitril-valsartan reverse cardiac remodeling (LVEF and LV size) at 9 months as 
assessed by 2D and automatic 3D-echocardiogram from Gonzales-Torres et al (2018) 
 
5.3 Applicability 
Both of the articles are further analyzed from its applicability aspect with respect to its 
implementation in Indonesia. In its implementation of our case, the studies have a significantly 
older range of age, where in the study it was from 58-77 years old, while our patient was still 
41 years old. ARNI has already been distributed in Indonesia in the form of a tablet, although 
its usage is still minimal in comparison to another group of drugs such as ACE Inhibitor and 
ARB, as it was confined by the price and its BPJS coverage.  Benefit  and  Harm  aspect  from  
this  treatment  can  be said  to  be more beneficial as the level of left ventricle ejection 
fraction was significantly better in patients that took ARNI for a certain amount of time 
compared to those that took ACE Inhibitor alone. 
Table 6. Critical Appraisal of importance aspect of meta-analysis Wang et al (2019) 
Parameter Wang et al (2018) Gonzales-Torres et al (2010) 
Similarities of research subject    
with the patient. 
 
The age range of patients in the 
study is 58.0 to 78.6 years, and 
76.6% of subjects were male. In 
our case, the patient is a male, 
The range of age in the studyis 69 
± 8 years old in the first part, and 
70 ± 8in the second part. 76% of 
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41 years old, which is far below 
the range 
Population   gathered   for   the 
study were conducted 
worldwide, which  include  the 
Asian population and was 
appropriate to our case 
The drugs used to control our 
patient blood pressure is ACE- 
Inhibitor,  which  is  the  same 
group to the study control. 
 
the patient is  a  male,  41  years  
old, which is far below the 
range.Population gathered for 
the study were from Spain only 
The  drugs  used  to  control our 
patient blood pressure is ACE-
Inhibitor, which is the same group 
to the study control. 
Feasibility of therapy in an 
everyday clinical setting 
 
Angiotensin-Receptor Neprisylin Inhibitor has already been 
distributed in Indonesia under the name LCZ696 or Entresto, 
although it is still rarely used in clinical practice. LCZ96 is available 
in the form of tablet 50 mg to be consumed twice a day. In 
Indonesia, the tablet is still fairly expensive, with the approximate 
price of Rp. 20.000 per tablet and is not covered by BPJS and there is 
no generic form just yet. In comparison, ACE Inhibitor such as 
Enalapril or Ramipril is Rp500 per tablet and is covered by BPJS. As 
such, the usage of ACE Inhibitor is much more common in 
Indonesia. From the price and coverage perspective, ACE Inhibitor 
can be said to be more feasible and beneficial 
Benefit of Harm Wang et al and Gonzales-Torres et al show that there are significant 
changes in terms of cardiac reverse remodeling, in which ARNI is 
able to reverse cardiac remodelling better than ACE-I, where the 
level of left ventricle ejection fraction was significantly better in 
patients that took ARNI for a certain amount of time. 
 
6. Discussion 
According to the aspect of validity for its critical appraisal, the meta-analysis from Wang et al 
(2019) and RCT from Gonzales-Torres et al (2018) can be said to be valid, although another 
additional study with a high level of evidence such as meta-analysis and systematic review can 
prove to be beneficial in this EBCR.  
In the study from Wang et al (2019), no heterogeneity was found from each of its parameters, 
so the effect from each study and their overall effect from the parameters can be used as a valid 
benchmark. The study from Gonzales-Torres et al (2018) was different in that the study was a 
prospective study, as 250 patients were treated with the same control and intervention for 9 
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validity of this study.  Overall, both of the studies were deemed to be valid and can be used as a 
benchmark for a treatment recommendation for the illustrated case in this EBCR. 
In the aspect of Importance in this EBCR, the aspect can be assessed through the level of 
cardiac reverse remodeling index, in which in this case was the left ventricular ejection volume. 
(LVEF). The intervention used was ARNI versus ACE-Inhibitor as its control. Both of the 
studies showed similar results. A meta-analysis from Wang et al (2019) showed that there is at 
least 5% of improvement of LVEF from the patients using ARNI compared to ACE-Inhibitor 
only, where the number is shown was proven to be statistically significant. Similarly, the study 
from Gonzales-Torres et al,  where in 2D and 3D examination by echocardiography, there were 
at least 5% of improvement of LVEF in patients treated using ARNI, which was also statistically 
significant. Both of the study used patients with similar characteristics, although only the study 
from Wang et al(2019) was multi-centered. Study from Wang et al(2019) is a meta-analysis that 
includes multiple studies, as such was shown to be a more reliable study. 
The primary outcome of both  studies was to assess the level of cardiac reverse 
remodeling through LVEF, however, it is important to assess the other parameter for its 
efficacy. Aside from LVEF, Wang et al(2019) also assessed the functional capacity of the heart 
through NYHA class, other CRR indices such as Left Ventricle Diastolic Diameter(LVDD), 
end-systolic and diastolic volume (ESV and EDV), and biomarkers in  both  ARNI and  ACE-
Inhibitor  group. On  the other hand,  Gonzales-Torres  et al(2018) only assess NYHA and 
LVDD as its additional parameters of cardiac reverse remodeling aspect. In its value, both of the 
studies shows a similar result where ARNI seems to be significantly better in its efficacy in 
comparison to ACE-Inhibitor (p-value <0.05). Based on that statement, it can be concluded that 
the usage of ARNI has a more beneficial effect compared to ACE-Inhibitor based on its 
parameters. The applicability aspect of heart failure treatment using ARNI should also be 
assessed.  
The population of Wang et al (2019) study was worldwide and multicenter study, which includes 
Asian population, as such it can be also be implemented in Indonesia, although study with 
Indonesian-only population should give a higher applicability level. The dosage of ARNI or 
ACE-Inhibitor in the studies were not given, as such it cannot be correlated to the case 
illustrated in this EBCR. From its availability, ARNI has already been distributed in Indonesia 
under the name LCZ69 or Entresto, however, it is not yet covered by BPJS nor has a generic 
version, thus, the usage of ARNI is still very limited for the general population in Indonesia, 
especially in BPJS era.  
7. Conclusion 
Based on the critical appraisal, studies from Wang et al (2019) and Gonzales- Torres et al 
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according to the study, where the improvement level of left ventricle eject fraction was 
statistically significant. The applicability of ARNI, in this case, is still debatable as it is not 
covered by BPJS and no generic form are widely distributed.  
Recommendation 
Further research specific to Indonesia population is recommended to give more precise data to be 
implemented to the case 
REFERENCES 
[1]  H. T. F. G. Bui AL, ―Epidemiology and risk profile of heart failure,‖ Nature Reviews 
Cardiology, vol. 8, no. 1, p. 30, 2011 Jan.  
[2]  V. T, ―Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 
1990–2010: a systematic analysis for the Global Burden of Disease Study 2010,‖ The 
lancet, vol. 380, no. 9859, pp. 2163-2196., 2012.  
[3]  M. D, ―Heart disease and stroke statistics—2016 update: a report from the American Heart 
Association,‖ Circulation, vol. 133, no. 4, pp. e38-60, 2016.  
[4]  F. G. Ziaeian B, ―Epidemiology and aetiology of heart failure,‖ Nature Reviews 
Cardiology, vol. 13, no. 6, p. 368, 2016.  
[5]  Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI, Jakarta: Riset 
Kesehatan Dasar, 2018.  
[6]  G. J. H. B. Neubauer BE, ―Heart Failure: Optimizing Recognition and Management in 
Outpatient Settings,‖ Prim Care Clin Off Pract, vol. 45, no. 1, p. 63–79, 2018.  
[7]  W. H. M. J. Jorsal A, ―Heart Failure: Epidemiology, Pathophysiology, and Management of 
Heart Failure in Diabetes Mellitus,‖ Endocrinol Metab Clin North Am, vol. 47, no. 1, p. 
117–35, 2018.  
[8]  G. A. Malek V, ―Neprilysin inhibitors: A new hope to halt the diabetic cardiovascular and 
renal complications?,‖ Biomed Pharmacother, vol. 90, p. 7529, 2017.  
[9]  P. M. D. R. P. J. Dargad RR, ―Sacubitril/valsartan: A novel angiotensin receptor-neprilysin 
inhibitor,‖ Indian Heart J, vol. 172, pp. 82-95, 2018.  
[10]  Z. R. L. C. C. Q. X. T. L. D. Wang Y, ―Effects of the Angiotensin-Receptor Neprilysin 
Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis,‖ J Am Heart Assoc, vol. 8, no. 
13, p. e012272, 2019.  
[11]  D. D. C. C. R. M. M. D. L. G. C. R. A. J. Gonzales-Torres L, ―Angiotensin-neprilysin 
inhibition further reverses cardiac remodeling as compared to angiotensin inhibition in 
reduced heart failure patients,‖ Clinical Cardiology Journal Volume II, vol. 2, 2018.  
 
 
 
